Document:

Form of Preferred Stock Purchase Warrant

 Exhibit 4.2 
 On March 21, 2005, Transcept Pharmaceuticals, Inc. (“TPI”) issued warrants in connection with a bridge financing to the individuals and entities listed below (the “Warrants”). The form of
Warrant used is set forth below as part of this Exhibit 4.2. 
 On January 30, 2009, TPI and Novacea, Inc. (“Novacea”)
completed a merger (the “Merger”) whereby TPI became a wholly owned subsidiary of Novacea, and Novacea changed its name to “Transcept Pharmaceuticals, Inc.” (with such post-closing entity being referred to as
“Transcept”). In connection with the Merger, the Warrants became exercisable for shares of Transcept common stock at the same exchange rate used in the Merger to exchange outstanding TPI capital stock (0.14134 shares of Transcept common
stock for each exchanged share of TPI). The share numbers set forth below reflect the approximate post-Merger shares into which such Warrants may be exercised. The exercise price per share for the Warrants was similarly adjusted, and, as of the
closing of the Merger, was approximately $1.415 per share of Transcept common stock. 
  

			
	 Warrantholder
	  	Post - Merger Shares
	 Biotechnology Development Fund IV Affiliates, L.P.
	  	325
	 Biotechnology Development Fund IV, L.P.
	  	17,630
	 David Day
	  	111
	 Michael Day
	  	111
	 Ronald D. Day
	  	111
	 Hamilton BioVentures, L.P.
	  	32,322
	 Montreux Equity Partners II SBIC, L.P.
	  	17,956
	 Montreux Equity Partners III SBIC, L.P.
	  	17,956
	 Glenn A. Oclassen, Sr.
	  	1,098
	 Peninsula Equity Partners SBIC, L.P.
	  	5,985
	 Michael Victor Petruzelli Trust
	  	109
	 Jerrold F. Petruzelli
	  	218
	 Robert and Linda Reese
	  	153
	 Nikhilesh N. Singh
	  	307
	 Thomas B. Soloway Revocable Family Trust
	  	153

 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED. 
 TRANSORAL PHARMACEUTICALS, INC. 
 WARRANT TO PURCHASE SHARES 
 Issuance Date: March 21, 2005 
 This Warrant is issued to
                             by TransOral Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), pursuant to the terms of that certain Note and Warrant Purchase Agreement (the “Note Purchase Agreement”) of even date herewith, in connection with the Company’s issuance to the holder of this
Warrant of a Subordinated Convertible Promissory Note (the “Note”). 
 1. Purchase of Shares. Subject to the terms
and conditions hereinafter set forth and set forth in the Note Purchase Agreement, the holder of this Warrant is entitled, upon surrender of this Warrant at the principal office of the Company (or at such other place as the Company shall notify the
holder hereof in writing), to purchase from the Company up to the number of fully paid and nonassessable Shares (as defined below), that equals the quotient obtained by dividing (a) the Warrant Coverage Amount (as defined below) by (b) the
Exercise Price (as defined below). 
 2. Definitions. 
 (a) Exercise Price. The exercise price for the Shares shall be the price per share of equity securities sold to investors in a
Qualified Equity Financing; provided, that in the event that a Qualified Equity Financing does not occur on or prior to December 31, 2005, the Holder may elect to exercise this Warrant for shares of Series B Preferred Stock at an exercise price
of $0.20 per share (as adjusted for any stock splits, stock dividends, reclassifications or the like). 
 (b) Exercise
Period. This Warrant shall be exercisable, in whole or in part, during the term commencing on the closing date of a Qualified Equity Financing (as defined below) and ending on the expiration of this Warrant pursuant to Section 12 hereof;
provided, that in the event that a Qualified Equity Financing does not occur on or prior to December 31, 2005, this Warrant may, at the option of the Holder, be exercisable for shares of Series B Preferred Stock commencing January 1, 2006.

  

 -1- 

 (c) Warrant Coverage Amount. The term “Warrant Coverage Amount”
shall mean that amount which equals 25% of the principal amount of the Note. 
 (d) The Shares. The term
“Shares” shall mean the class and series of preferred stock issued to investors in a Qualified Equity Financing; provided, that in the event that a Qualified Equity Financing does not occur on or prior to December 31, 2005,
“Shares” shall mean, at the option of the Holder, the Series B Preferred Stock of the Company. 
 (e)
Qualified Equity Financing. The term “Qualified Equity Financing” is an equity financing pursuant to which the Company sells shares of a new series of preferred stock with an aggregate sales price of not less than
$10,000,000, including any and all convertible bridge notes (including Notes issued under the Note Purchase Agreement) which are converted into preferred stock and with the principal purpose of raising capital. 
 (f) Acquisition. The term “Acquisition” shall mean (i) any consolidation or merger involving the Company
pursuant to which the Company’s stockholders own less than fifty percent (50%) of the voting securities of the surviving entity or (ii) the sale of all or substantially all of the assets of the Company; provided, that an Acquisition
shall not include a merger effected exclusively for the purpose of changing the domicile of the Company or an equity financing in which the Company is the surviving corporation. 
 3. Method of Exercise. While this Warrant remains outstanding and exercisable the Holder may exercise, in whole or in part, the purchase rights
evidenced hereby. Such exercise shall be effected by: 
 (a) the surrender of the Warrant, together with the notice of
exercise in the form attached hereto as Exhibit A to the President of the Company at its principal offices; and 
 (b)
the payment to the Company of an amount equal to the aggregate Exercise Price for the number of Shares being purchased. 
 4. Net
Exercise. In lieu of cash exercising this Warrant, the holder of this Warrant may elect to receive shares equal to the value of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the
Company together with notice of such election, in which event the Company shall issue to the holder hereof a number of Shares computed using the following formula: 

					
	  	  	Y (A - B)	  	 
	X =	  	A	  	

 Where 
 X — The number of Shares to be issued to the holder of this Warrant. 
 Y — The number of Shares purchasable under this Warrant. 
 A — The fair market value of one Share. 
 B — The Exercise Price (as adjusted to the date of such calculations). 
  

 -2- 

 For purposes of this Section 4, the fair market value of a Share shall mean the average of the
closing bid and asked prices of Shares quoted in the over-the-counter market in which the Shares are traded or the closing price quoted on any exchange on which the Shares are listed, whichever is applicable, as published in the Western Edition of
The Wall Street Journal for the ten (10) trading days prior to the date of determination of fair market value (or such shorter period of time during which such stock was traded over-the-counter or on such exchange). If the Shares are not
traded on the over-the-counter market or on an exchange, the fair market value shall be the price per Share that the Company could obtain from a willing buyer for Shares sold by the Company from authorized but unissued Shares, as such prices shall
be determined in good faith by the Company’s Board of Directors. 
 5. Certificates for Shares. Upon the exercise of the purchase
rights evidenced by this Warrant, one or more certificates for the number of Shares so purchased shall be issued as soon as practicable thereafter. 
 6. Issuance of Shares. The Company covenants that the Shares, when issued pursuant to the due exercise of this Warrant, will be duly and validly issued, fully paid and nonassessable and free from all taxes, liens, and charges with
respect to the issuance thereof (other than any encumbrances created by or imposed upon the Holder). 
 7. Adjustment of Exercise Price
and Number of Shares. The number of and kind of securities purchasable upon exercise of this Warrant and the Exercise Price shall be subject to adjustment from time to time as follows: 
 (a) Subdivisions, Combinations and Other Issuances. If the Company shall at any time prior to the expiration of this Warrant
subdivide the Shares, by split-up or otherwise, or combine its Shares, or issue additional shares of its Shares as a dividend, the number of Shares issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of
a subdivision or stock dividend, or proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the purchase price payable per share, but the aggregate purchase price payable for the total number of Shares
purchasable under this Warrant (as adjusted) shall remain the same. Any adjustment under this Section 7(a) shall become effective at the close of business on the date the subdivision or combination becomes effective, or as of the record date of
such dividend, or in the event that no record date is fixed, upon the making of such dividend. 
 (b) Reclassification,
Reorganization and Consolidation. Subject to Section 12 hereof, in case of any reclassification, capital reorganization, or change in the capital stock of the Company (other than as a result of a subdivision, combination, or stock dividend
provided for in Section 7(a) above), then the Company shall make appropriate provision so that the holder of this Warrant shall have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that
payable upon the exercise of this Warrant, the kind and amount of shares of stock and other 

  

 -3- 

 
securities and property receivable in connection with such reclassification, reorganization, or change by a holder of the same number of Shares as were
purchasable by the holder of this Warrant immediately prior to such reclassification, reorganization, or change. In any such case appropriate provisions shall be made with respect to the rights and interest of the holder of this Warrant so that the
provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities and property deliverable upon exercise hereof, and appropriate adjustments shall be made to the purchase price per share payable hereunder,
provided the aggregate purchase price shall remain the same. 
 (c) Redemption or Conversion. If all of the Shares are
redeemed or converted into shares of Common Stock, then this Warrant shall automatically become exercisable for that number of shares of Common Stock equal to the number of shares of Common Stock that would have been received if this Warrant had
been exercised in full and the Shares received thereupon had been simultaneously converted into shares of Common Stock immediately prior to such event, and the Exercise Price shall be automatically adjusted to equal the number obtained by dividing
(i) the aggregate Exercise Price of the Shares for which this Warrant was exercisable immediately prior to such redemption or conversion, by (ii) the number of shares of Common Stock for which this Warrant is exercisable immediately after
such redemption or conversion. 
 (d) Notice of Adjustment. When any adjustment is required to be made in the number or
kind of shares purchasable upon exercise of the Warrant, or in the Exercise Price, the Company shall promptly notify the holder of such event and of the number of Shares or other securities or property thereafter purchasable upon exercise of this
Warrant. 
 8. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the
exercise of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor on the basis of the Exercise Price then in effect. 
 9. Restrictive Legend. 
 The Shares (unless registered under the Act) shall be stamped or imprinted
with a legend in substantially the following form: 
 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT
WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION
THEREFROM UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 
 10. Warrants Transferable. Subject to compliance with the terms
and conditions of this Section, this Warrant and all rights hereunder are transferable, in whole, without charge to the holder hereof (except for applicable transfer taxes), upon surrender of this Warrant (including Exhibit B hereto) properly
endorsed or accompanied by written instructions of transfer. With respect to any 

  

 -4- 

 
offer, sale or other disposition of this Warrant or any Shares acquired pursuant to the exercise of this Warrant prior to registration of such Warrant or
Shares, the holder hereof agrees to give written notice to the Company prior thereto, describing briefly the manner thereof, together with a written opinion of such holder’s counsel, or other evidence, if requested by the Company, to the effect
that such offer, sale or other disposition may be effected without registration or qualification (under the Act as then in effect or any federal or state securities law then in effect) of this Warrant or the Shares and indicating whether or not
under the Act certificates for this Warrant or the Shares to be sold or otherwise disposed of require any restrictive legend as to applicable restrictions on transferability in order to ensure compliance with such law. Upon receiving such written
notice and reasonably satisfactory opinion or other evidence, if so requested, the Company, as promptly as practicable, shall notify such holder that such holder may sell or otherwise dispose of this Warrant or such Shares, all in accordance with
the terms of the notice delivered to the Company. If a determination has been made pursuant to this Section that the opinion of counsel for the holder or other evidence is not reasonably satisfactory to the Company, the Company shall so notify the
holder promptly with details thereof after such determination has been made. Each certificate representing this Warrant or the Shares transferred in accordance with this Section shall bear a legend as to the applicable restrictions on
transferability in order to ensure compliance with such laws, unless in the aforesaid opinion of counsel for the holder, such legend is not required in order to ensure compliance with such laws. The Company may issue stop transfer instructions to
its transfer agent in connection with such restrictions. 
 11. No Rights of Stockholders. No holder of this Warrant shall be
entitled, as a Warrant holder, to vote or receive dividends or be deemed the holder of the Shares or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be
construed to confer upon the holder of this Warrant, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or
withhold consent to any corporate action (whether upon any recapitalization, issuance of stock, reclassification of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive
dividends or subscription rights or otherwise until the Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. 
 12. Expiration of Warrant. This Warrant shall expire and shall no longer be exercisable upon the earlier to occur of: 
 (a) 5:00 p.m., California local time, on the seven (7) year anniversary of the closing of a Qualified Equity Financing;
provided, that this Warrant shall in no event be exercisable for shares of Series B Preferred Stock pursuant to Section 2 hereof after December 31, 2012; 
 (b) the closing of an Acquisition, provided Company provides 15 day prior written notice of the closing of the Acquisition; or 

 

 -5- 

 (c) the effectiveness of a registration statement filed pursuant to the Act for the
initial public offering of the Company’s Common Stock, provided Company provides 15 day prior written notice of such registration statement. 
 13. Notices. All notices and other communications required or permitted hereunder shall be given in accordance with the Note Purchase Agreement. 
 14. “Market Stand-Off” Agreement. Holder hereby agrees to be bound by the provisions of Section 1.14 of that certain Amended and Restated Investor Rights Agreement dated as of July 14, 2003
by and among the Company and the other parties thereto, as may be amended from time to time, as if the Holder were a “Holder” thereunder. 
 Notwithstanding the foregoing, the obligations described in this Section 14 shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms which may be promulgated in the future, or
a registration relating solely to an SEC Rule 145 transaction. 
 15. Reservation of Stock. For so long as this Warrant is
outstanding, the Company will at all times reserve and keep available, solely for the issuance and delivery upon the exercise of this Warrant, such Shares and other stock, securities and property, as from time to time shall be issuable upon the
exercise of this Warrant; provided, however, that (i) no shares of the preferred stock issued to investors in a Qualified Equity Financing shall be authorized and available for issuance upon exercise of this Warrant until such time as the
Qualified Equity Financing, and (ii) the Company shall not be required to keep available shares of Series B Preferred Stock for issuance and delivery upon exercise of this Warrant until the date beginning January 1, 2006 (provided there
has not been a Qualified Equity Financing prior to such date). 
 16. Amendment or Waiver. Any term of this Warrant may be amended or
waived upon written consent of the Company and the holders of at least 50% of the Shares issuable upon exercise of outstanding warrants issued pursuant to the Note Purchase Agreement. By acceptance hereof, the Holder acknowledges that in the event
the required consent is obtained, any term of this Warrant may be amended or waived with or without the consent of the Holder; provided, however, that any amendment hereof that would materially adversely affect the Holder in a manner different from
the holders of the remaining warrants issued pursuant to the Note Purchase Agreement shall also require the consent of this Holder. 
 17.
Governing Law. This Warrant and all actions arising out of or in connection with this Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard to the conflicts of law provisions of
the State of California, or of any other state. 
  

 -6- 

 18. Survival. Unless otherwise provided herein, the rights and obligations of the Company, of the
holder of this Warrant and of the holder of the Shares issued upon exercise of this Warrant, shall survive the exercise of this Warrant. 
  

			
	TRANSORAL PHARMACEUTICALS, INC.
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  

	
	Agreed and Acknowledged:
	
	  
	

  

 -7- 

 EXHIBIT A 
 NOTICE OF EXERCISE 
  

	TO:	TransOral Pharmaceuticals, Inc. 

	    	300 Tamal Plaza Ste. 220, 

	    	Corte Madera, CA 94925 

	    	Attention: President 

 1. The undersigned hereby elects to
purchase                      shares of
                     pursuant to the terms of the attached Warrant. 
 2. Method of Exercise (Please initial the applicable blank): 

	 	          	 The undersigned elects to exercise the attached Warrant by means of a cash payment, and tenders herewith payment in full for the purchase price of the shares being
purchased, together with all applicable transfer taxes, if any. 

  

	 	          	 The undersigned elects to exercise the attached Warrant by means of the net exercise provisions of Section 4 of the Warrant. 

 3. Please issue a certificate or certificates representing said Shares in the name of the undersigned or in such other name as is specified below:

 _______________________________________________ 
 (Name) 
 _______________________________________________ 
 _______________________________________________ 
 (Address) 
 4. The undersigned hereby represents and warrants that the aforesaid Shares are being acquired for the account of the
undersigned for investment and not with a view to, or for resale, in connection with the distribution thereof, and that the undersigned has no present intention of distributing or reselling such shares and all representations and warranties of the
undersigned set forth in Section 10 of the attached Warrant (including Section 10 (e) thereof) are true and correct as of the date hereof. 
  

					
		 		 	
	 	 		 	  
		 		 	(Signature)
		 		 	
		 		 	  
		 		 	(Name)
		 		 	
	  	 		 	  
	(Date)	 		 	(Title)

 EXHIBIT B 
 FORM OF TRANSFER 
 (To be signed only upon transfer of Warrant) 
 FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto _______________________________________________ the right represented by the attached
Warrant to purchase ____________ shares of ________________________ of TransOral Pharmaceuticals, Inc. to which the attached Warrant relates, and appoints ______________ Attorney to transfer such right on the books of __________, with full power of
substitution in the premises. 
 Dated: ____________________ 
  

	
	
	
	  
	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)
	
	Address:___________________________________
	               ___________________________________
               ___________________________________

  

	
	Signed in the presence of:Preferred Stock Purchase Warrant

 Exhibit 4.3 
 Execution 4/13/06 
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY
NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER THEREOF REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT
REQUIRED UNDER THE SECURITIES ACT OF 1933 ACT AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. 
 WARRANT AGREEMENT 
 To Purchase Shares of the Series C Preferred Stock of 
 TransOral Pharmaceuticals, Inc. 
 Dated as of April 13, 2006 (the “Effective Date”) 
 WHEREAS, TransOral Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has entered into a Senior Loan and Security
Agreement of even date herewith (the “Loan Agreement”) with Hercules Technology Growth Capital, Inc., a Maryland corporation (the “Warrantholder”); 
 WHEREAS, the Company desires to grant to Warrantholder, in consideration for, among other things, the financial accommodations provided for in the Loan
Agreement, the right to purchase shares of its Series C Preferred Stock pursuant to this Warrant Agreement the “Agreement”); 
 NOW, THEREFORE, the Company and Warrantholder agree as follows: 
  

	1.	GRANT OF THE RIGHT TO PURCHASE PREFERRED STOCK. 

 For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the conditions hereinafter set forth, to subscribe for and purchase, from the Company, fully paid and
non-assessable shares of the Preferred Stock (as defined below) at a purchase price of $1.15 per share (the “Exercise price”). The number of Shares is equal to 5% of the aggregate Advances made under the Loan and Security Agreement
dated as of the Effective Date between Company and Warrantholder divided by the Exercise Price. The number and Exercise Price of such shares are subject to adjustment as provided in Section 8. As used herein, the following terms shall have the
following meanings: 
 “Act” means the Securities Exchange Act of 1933, as amended. 
 “Charter” means the Company’s Certificate of Incorporation, as may be amended from time to time. 
 “Common Stock” means the Company’s common stock; 
  

 1. 

 “Initial Public Offering” means the initial underwritten public offering
of the Company’s Common Stock pursuant to a registration statement under the Act, which public offering has been declared effective by the Securities and Exchange Commission (“SEC”); 
 “Merger Event” means (i) a merger or consolidation involving the Company in which the Company is not the surviving
entity, or in which the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged for shares of capital stock of another entity, or (ii) the sale of all or substantially all of the assets of the Company.

 “Preferred Stock” means the Series C Preferred Stock of the Company and any other stock into or for which
the Series C Preferred Stock may be converted or exchanged, and upon and after the occurrences of an event which results in the automatic or voluntary conversion, redemption or retirement of all (but not less than all) of the outstanding shares of
such Preferred Stock, including, without limitation, the consummation of an Initial Public Offering of the Common Stock in which such a conversion occurs, then from and after the date upon which such outstanding shares are so converted, redeemed or
retired, “Preferred Stock” shall mean such Common Stock; and 
 “Purchase Price” means, with
respect to any exercise of this Warrant, an amount equal to the Exercise Price as of the relevant time multiplied by the number of shares of Preferred Stock requested to be exercised under this Warrant pursuant to such exercise. 
  

	2.	TERM. 

 Except as otherwise provided for herein, the
term of this Warrant and the right to purchase Preferred Stock as granted herein (the “Warrant”) shall commence on the Effective Date and shall be exercisable for a period ending upon the earliest to occur of (i) ten (10) years
from the Effective Date; or (ii) five (5) years after the Initial Public Offering. Notwithstanding anything herein to the contrary, upon the consummation of a Merger Event where the consideration to the Company is cash or publicly traded
securities, this Warrant shall automatically be exercised pursuant to Section 3 hereof, without any action by the holder of this Warrant. 
  

	3.	EXERCISE. 

 (a) Exercise. The purchase rights
set forth in this Warrant are exercisable by the Warrantholder, in whole or in part, at any time, or from time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a notice of
exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”), duly completed and executed, together with payment of the Purchase Price. Promptly upon receipt of the Notice of Exercise and the payment of the
Purchase Price in accordance with the terms set forth below, and in no event later than ten (10) business days thereafter, the Company shall issue to the Warrantholder a certificate for the number of shares of Preferred Stock purchased and
shall execute the acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of Exercise”) indicating the number of shares which remain subject to future purchases, if any. The date which such
certificate shall be deemed to have been issued shall be the date of exercise of the Warrant in the manner set forth herein. 
  

 2. 

 The Purchase Price may be paid at the Warrantholder’s election either (i) by cash or check, or
(ii) if the fair market value of one share of the Preferred Stock is greater than the Exercise Price then in effect, by surrender of all or a portion of the Warrant for shares of Preferred Stock to be exercised under this Warrant and, if
applicable, an amended Agreement representing the remaining number of shares purchasable hereunder, as determined below (“Net Issuance”). If the Warrantholder elects the Net Issuance method, the Company will issue Preferred Stock in
accordance with the following formula: 
  

							
		 		  		  	 X = Y(A-B)
             A

				
	Where:	 		  	X =	  	the number of shares of Preferred Stock to be issued to the Warrantholder.
				
		 		  	Y =	  	the number of shares of Preferred Stock requested to be exercised under this Warrant.
				
		 		  	A =	  	the fair market value of one (1) share of Preferred Stock at the time of issuance of such shares of Preferred Stock.
				
		 		  	B =	  	the Exercise Price.

 For purposes of the above calculation, current fair market value of Preferred Stock shall mean
with respect to each share of Preferred Stock: 
 (i) if the exercise is made concurrent with the closing of an Initial Public
Offering, and if the Company’s Registration Statement relating to such Initial Public Offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to Public”
of the Common Stock specified in the final prospectus with respect to the offering and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; 
 (ii) if the exercise is after, and not in connection with, an Initial Public Offering, and: 
 (1) if the Common Stock is traded on a securities exchange, the fair market value shall be deemed to be the product of (x) the
average of the closing prices over a five (5) trading day period ending the first trading day before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each
share of Preferred Stock is convertible at the time of such exercise; or 
 (2) if the Common Stock is traded
over-the-counter, the fair market value shall be deemed to be the product of (x) the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day trading day period ending the first
trading day before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise. 
  

 3. 

 (iii) if at any time the Common Stock is not listed on any securities exchange or quoted
in the NASDAQ National Market or the over-the-counter market, the current fair market value of Preferred Stock shall be the product of (x) the highest price per share which the Company could obtain from a willing buyer (not a current employee
or director) for shares of Common Stock sold by the Company, ‘from authorized but unissued shares, as most recently determined in good faith by its Board of Directors and (y) the number of shares of Common Stock into which each share of
Preferred Stock is convertible at the time of such exercise, unless the exercise is made concurrent with a Merger Event pursuant to which the Company is not the surviving party, in which case the fair market value of Preferred Stock shall be deemed
to be the per share value received by the holders of the Company’s Preferred Stock on a common equivalent basis pursuant to such Merger Event. 
 Upon partial exercise by either cash or Net Issuance, the Company shall promptly issue an amended Agreement representing the remaining number of shares purchasable hereunder. All other terms and conditions of such amended Agreement shall be
identical to those contained herein, including, but not limited to the Effective Date hereof. 
 (b) Exercise Prior to Expiration. To
the extent this Warrant is not previously exercised as to all Preferred Stock subject hereto, and if the fair market value of one share of the Preferred Stock is greater than the Exercise Price then in effect, this Warrant shall be deemed
automatically exercised pursuant to Section 3(a) (even if not surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of on share of the Preferred Stock upon such expiration shall be
determined pursuant to Section 3(a). To the extent this Warrant or any portion thereof is deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of
Preferred Stock, if any, the Warrantholder is to receive by reason of such automatic exercise. 
  

	4.	RESERVATION OF SHARES. 

 During the term of this
Warrant, the Company will at all times have authorized and reserved a sufficient number of shares of its Preferred Stock to provide for the exercise of the rights to purchase Preferred Stock as provided for herein, and shall have authorized and
reserved a sufficient number of shares of its Common Stock to provide for the conversion of the preferred Shares available hereunder. 
  

	5.	NO FRACTIONAL SHARES OR SCRIP. 

 No fractional
shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor upon the basis of the Exercise Price then in effect. 

 

 4. 

	6.	REGISTRATION RIGHTS. 

 The holder of this Warrant
shall be made a party to that certain Amended and Restated Investor Rights Agreement (the “Investor Rights Agreement”) dated as of October 25, 2005, among the Company and the Stockholders, as defined therein, in accordance with that
certain Joinder Agreement attached hereto as Exhibit IV. 
  

	7.	WARRANTHOLDER REGISTRY. 

 The Company shall maintain
a registry showing the name and address of the registered holder of this Warrant. Warrantholder’s initial address, for purposes of such registry, is set forth below Warrantholder’s signature on this Warrant. Warrantholder may change such
address by giving written notice of such changed address to the Company. 
  

	8.	ADJUSTMENT RIGHTS. 

 The Exercise Price and the
number of shares of Preferred Stock purchasable hereunder are subject to adjustment, as follows: 
 (a) Merger Event. Subject to the
termination provisions contained in Section 2 hereof, if at any time there shall be a Merger Event, then, as a part of such Merger Event, lawful provision shall be made so that the Warrantholder shall thereafter be entitled to receive, upon
exercise of this Warrant, the number of shares of preferred stock or other securities or property of the successor corporation resulting from such Merger Event that would have been issuable if Warrantholder had exercised this Warrant immediately
prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of
the Warrantholder after the Merger Event to the end that the provisions of this Warrant (including adjustments of the Exercise Price and number of shares of Preferred Stock purchasable) shall be applicable in their entirety, and to the greatest
extent possible. Without limiting the foregoing, in connection with any Merger Event, upon the closing thereof, the successor or surviving entity shall assume the obligations of this Warrant. 
 (b) Reclassification of Shares. Except as set forth in Section 8(a), if the Company at any time shall, by combination, reclassification,
exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Warrant exist into the same or a different number of securities of any other class or classes, this Warrant shall thereafter
represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Warrant immediately prior to such
combination, reclassification, exchange, subdivision or other change. 
 (c) Subdivision or Combination of Shares. If the
Company at any time shall combine or subdivide its Preferred Stock, (i) in the case of a subdivision, the Exercise price shall be proportionately decreased, and the number of shares of Preferred Stock issuable upon exercise of this Warrant
shall be proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be proportionately increased, and the number of shares of Preferred Stock issuable upon the exercise of this Warrant shall be proportionately
decreased. 
  

 5. 

 (d) Stock Dividends. If the Company at any time while this Warrant is outstanding and unexpired
shall: 
 (i) pay a dividend with respect to the Preferred Stock payable in preferred Stock, then the Exercise Price
shall be adjusted, from and after the date of determination of shareholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a
fraction (A) the numerator of which shall be the total number of shares of Preferred Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Preferred Stock
outstanding immediately after such dividend or distribution; or 
 (ii) make any other distribution with respect to
Preferred Stock (or stock into which the Preferred Stock is convertible), except any distribution specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that the
Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate share of any such distribution as though it were the holder of the preferred Stock (or other stock for which the Preferred Stock is convertible) as of the record
date fixed for the determination of the shareholders of the Company entitled to receive such distribution. 
 (e) Antidilution Rights.
Additional antidilution rights applicable to the preferred Stock purchasable hereunder are as set forth in the Company’s Charter and shall be applicable with respect to the Preferred Stock issuable hereunder. The Company shall promptly
provide the Warrantholder with any restatement, amendment, modification or waiver of the Charter that materially affects the rights of the Preferred Stock; provided, that no such amendment, modification or waiver shall impair or reduce the
antidilution rights applicable to the Preferred Stock as of the date hereof unless such amendment, modification or waiver affects the rights of Warrantholder with respect to the Preferred Stock in the same manner as it affects all other holders of
Preferred Stock. For the avoidance of doubt, there shall be no duplicate anti-dilution adjustment pursuant to this subsection (f), the forgoing subsection (d) and the Company’s Charter. 
 (f) Notice of Adjustments. Whenever an adjustment to the Exercise price or the number of shares of Preferred Stock issuable upon exercise
of this Warrant is made pursuant to this Section 8, the Company shall send to the Warrantholder a notice setting forth, in reasonable detail, (i) the event requiring the adjustment, (ii) the amount of such adjustment, (iii) the method
by which such adjustment was calculated, (iv) the adjusted Exercise Price (if the Exercise price has been adjusted), and (v) the number of shares subject to purchase hereunder after giving effect to such adjustment, and shall cause such
notice to be mailed (by first class mail, postage. prepaid, or by reputable overnight courier with all charges prepaid) within thirty (30) days of such adjustment addressed to the Warrantholder at the address for Warrantholder set forth in the
registry referred to in Section 7. 
  

 6. 

	9.	REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

 (a) Reservation of Preferred Stock. The Preferred Stock issuable upon exercise of the Warrantholder’s rights has been duly and validly reserved and, when issued in accordance with the provisions of this Warrant, will be validly
issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, that the Preferred Stock issuable pursuant to this Warrant may be subject to restrictions on transfer
under state and/or federal securities laws and applicable agreements to which the Company or its security holders are parties. The Company has made available to the Warrantholder true, correct and complete copies of its Charter and current bylaws.
The issuance of certificates for shares of Preferred Stock upon exercise of this Warrant shall be made without charge to the Warrantholder for any issuance tax in respect thereof, or other cost incurred by the Company in connection with such
exercise and the related issuance of shares of Preferred Stock; provided, that the Company shall not be required to pay any tax which may be payable in respect of any transfer and the issuance and delivery of any certificate in a name other
than that of the Warrantholder. 
 (b) Due Authority. The execution and delivery by the Company of this Warrant and the performance of
all obligations of the Company hereunder, including the issuance to Warrantholder of the right to acquire the shares of Preferred Stock and the Common Stock into which it may be converted, have been duly authorized by all necessary corporate action
on the part of the Company. This Warrant: (1) is not inconsistent with the Company’s Charter or current bylaws; (2) subject to the accuracy of the Warrantholder’s representations in Section 10, does not contravene any law or
governmental rule, regulation or order applicable to it; and (3) does not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contact or other instrument to which it is a party or by which it is
bound. This Warrant constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its respective terms. 
 (c) Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the
execution, delivery and performance by the Company of its obligations under this Warrant, except for the filing of notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be
effective by the time required thereby. 
 (i) Issued Securities. All issued and outstanding shares of Common
Stock, Preferred Stock or any other securities of the Company have been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock, Preferred Stock and any other securities were issued in full
compliance with all federal and state securities laws. Attached to this Warrant is a true and correct capitalization table of the Company. In accordance with the Company’s Charter, no shareholder of the Company has preemptive right to purchase
new issuances of the Company’s capital stock which right has not otherwise been waived in connection with the issuance of this Warrant. 
 (d) Other Commitments to Register Securities. Except as set forth in this Warrant and the Investor Rights Agreement, the Company is not, pursuant to the terms of any other agreement currently in existence, under any obligation to
register under the Act any of its presently outstanding securities or any of its securities which may hereafter be issued. 
  

 7. 

 (e) Exempt Transaction. Subject to the accuracy of the Warrantholder’s representations
in Section 10 (both at the time of the issuance of the Preferred Stock upon exercise of this Warrant and at the time of the issuance of the Common Stock upon conversion of the Preferred Stock), the issuance of the Preferred Stock upon exercise
of this Warrant, and the issuance of the Common Stock upon conversion of the Preferred Stock, will each constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act, in reliance upon Section 4(2)
thereof, and (ii) the qualification requirements of the applicable state securities laws. 
 (f) Compliance with Rule 144. If the
Warrantholder proposes to sell Preferred Stock issuable upon the exercise of this Warrant, or the Common Stock into which it is convertible, in compliance with Rule 144 promulgated by the SEC, then, upon Warrantholder’s written request to the
Company, the Company shall furnish to the Warrantholder, within ten days after receipt of such request, a written statement confirming the Company’s compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may
be amended from time to time. 
  

	10.	REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 

 This Warrant has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder: 
 (a) Investment Purpose. The right to acquire Preferred Stock or the Preferred Stock issuable upon exercise of the Warrantholder’s rights contained herein are being acquired for investment and not with a view to the sale or
distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in any public distribution of the same except pursuant to a registration or exemption. 
 (b) Private Issue. The Warrantholder understands (i) that the Preferred Stock issuable upon exercise of this Warrant is not registered under
the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant will be exempt from the registration and qualifications requirements thereof, and (ii) that the Company’s reliance on
such exemption is predicated on the representations set forth in this Section 10. 
 (c) Disposition of Warrantholder’s
Rights. In no event will the Warrantholder make a disposition of any of its rights to acquire Preferred Stock or Preferred Stock issuable upon exercise of such rights unless and until (i) it shall have notified the Company of the proposed
disposition, and (ii) if requested by the Company, it shall have furnished the Company with an opinion of counsel (which counsel may either be inside or outside counsel to the Warrantholder) reasonably satisfactory to the Company and its
counsel to the effect that (A) appropriate action necessary for compliance with the Act has been taken, or (B) an exemption from the registration requirements of the Act is available. Notwithstanding the foregoing, the restrictions imposed
upon the transferability of any of its rights to acquire Preferred Stock or Preferred Stock issuable on the exercise of such rights do not apply to transfers from the beneficial owner of any of the aforementioned securities to its nominee or from
such nominee to its beneficial owner, or to any transfers to an Affiliate (as such term is defined in the Act) of Warrantholder, and shall terminate as to any particular share of Preferred Stock when (1) such security shall have been
effectively registered under the Act and sold by the holder thereof in 

  

 8. 

 
accordance with such registration or (2) such security shall have been sold without registration in compliance with Rule 144 under the Act, or
(3) a letter shall have been issued to the Warrantholder at its request by the staff of the SEC or a ruling shall have been issued to the Warrantholder at its request by the SEC stating that no action shall be recommended by such staff or taken
by the SEC, as the case may be, if such security is transferred without registration under the Act in accordance with the conditions set forth in such letter or ruling and such letter or ruling specifies that no subsequent restrictions on transfer
are required. Whenever the restrictions imposed hereunder shall terminate, as hereinabove provided, the Warrantholder or holder of a share of Preferred Stock then outstanding as to which such restrictions have terminated shall be entitled to receive
from the Company, without expense to such holder, one or more new certificates for this Warrant or for such shares of Preferred Stock not bearing any restrictive legend. 
 (d) Financial Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability to bear the
economic risks of its investment. 
 (e) Risk of No Registration. The Warrantholder understands that if the Company does not
register with the SEC pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “1934 Act”), or file reports pursuant to Section l5(d) of the 1934 Act, or if a registration statement covering the securities
under the Act is not in effect when it desires to sell (i) the rights to purchase Preferred Stock pursuant to this Warrant or (ii) the preferred Stock issuable upon exercise of the right to purchase, it may be required to hold such
securities for an indefinite period. The Warrantholder also understands that any sale of (A) its rights hereunder to purchase Preferred Stock or (B) Preferred Stock issued or issuable hereunder which might be made by it in reliance upon
Rule 144 under the Act may be made only in accordance with the terms and conditions of that Rule. 
 (f) Accredited Investor.
Warrantholder is an “accredited investor” within the meaning of the Securities and Exchange Rule 501 of Regulation D, as presently in effect. 
 (g) Diligence. Warrantholder has had an opportunity to discuss the Company’s business, management and financial affairs with its management and an opportunity to review the Company’s
facilities. 
  

	11.	TRANSFERS AND LEGENDS. 

 (a) Subject to the
terms and conditions contained in Section 10, this Warrant and all rights hereunder are transferable in whole or in part by the Warrantholder and any successor transferee. The transfer shall be recorded on the books of the Company upon receipt
by the Company of a notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such
transfer. 
  

 9. 

 (b) Legend. The Preferred Stock (unless registered under the Act) shall be stamped or imprinted
with a legend in substantially the following form: 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SHARES UNDER
THE ACT, OR PURSUANT TO RULE 144 UNDER THE ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER THE ACT (EXCEPT THAT AN OPINION SHALL NOT BE REQUIRED WITH RESPECT TO A TRANSFER WITHOUT
CONSIDERATION TO AN AFFILIATE). THESE SECURITIES HAVE NOT BEEN QUALIFIED UNDER THE LAWS OF ANY STATE, INCLUDING THE DEPARTMENT OF CORPORATIONS OF THE STATE OF CALIFORNIA, OR THE STATE AGENCIES OF DELAWARE. IN THE ABSENCE OF AN EXEMPTION FROM
QUALIFICATION REQUIREMENT(S) UNDER APPLICABLE LAW, THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL. 
 Notwithstanding the foregoing, if the Preferred Stock has been held for one year from the later of the date of issuance by the Company or the date such Preferred Stock
was acquired from an “affiliate” of the Company (including periods of tacking, if any) and Warrantholder is not an “affiliate” of the Company (“affiliate” in each case, as defined in Rule 144 promulgated under the Act),
then the Company hereby agrees to reissue the Shares without the legend above promptly following the date it receives written notice from Warrantholder requesting such removal and reissuance. 
  

	12.	MISCELLANEOUS. 

 (a) Effective Date. The
provisions of this Warrant shall be construed and shall be given effect in all respects as if it had been executed and delivered by the Company on the date hereof. This Warrant shall be binding upon any successors or assigns of the Company. 

 (b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either
by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where Warrantholder will not have an adequate remedy at law and
where damages will not be readily ascertainable. 
 (c) Market Standoff. The Warrantholder shall be subject to the restrictions under
Section 1.14 of the Investor Rights Agreement to the same extent as the other parties thereto. 
 (d) No Impairment of Rights.
The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms
and in the taking of all such actions as may be necessary or appropriate in order to protect the rights of the Warrantholder against impairment. 
  

 10. 

 (e) Attorney’s Fees. In any litigation, arbitration or court proceeding between the Company
and the Warrantholder relating hereto, the prevailing party shall be entitled to reasonable attorneys’ fees and expenses and all costs of proceedings reasonably incurred in enforcing this Warrant. For the purposes of this Section 12(e),
attorneys’ fees shall include without limitation fees reasonably incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection
with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment.

 (f) Entire Agreement; Amendments. This Warrant constitute the entire agreement and understanding of the parties hereto in respect
of the subject matter hereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof. None of the terms
of this Warrant may be amended except by an instrument executed by each of the parties hereto. 
 (g) No Waiver. No omission or delay
by Warrantholder at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right or remedy to which
Warrantholder is entitled, nor shall it in any way affect the right of Warrantholder to enforce such provisions thereafter. 
 (h)
Survival. All agreements, representations and warranties contained in this Warrant or in any document delivered pursuant hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Warrant and the
expiration or other termination of this Warrant. 
 (i) Governing Law. This Warrant shall be governed by, and construed and enforced
in accordance with, the laws of the State of Delaware, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction, 
 (j) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Warrant may be brought in any state or federal court of competent jurisdiction located in the State of
California. By execution and delivery of this Warrant, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in Santa Clara County, California; (b) waives any objection as to jurisdiction or venue in Santa
Clara County, California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Warrant, Nothing
herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 
  

 11. 

 (k) Mutual Waiver of Jury Trial. Because disputes arising in connection with complex financial
transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a
judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY,
“CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. If this jury waiver is for any reason unenforceable, all disputes shall be resolved by judicial reference
under California Code of Civil Procedure Section 638. 
 (l) Specific Performance. Warrantholder and Company agree that either
may be irreparably damaged by any breach or threatened breach of this Warrant. Upon a breach or threatened breach of the terms, covenants and/or conditions of this Warrant by Warrantholder or Company, the other party shall, in addition to all other
remedies, be entitled to seek a temporary or permanent injunction and/or a decree for specific performance, in accordance with the provisions hereof. 
 (m) No Stockholder Rights. Prior to the exercise of this Warrant, the Warrantholder shall
not be entitled to vote or receive dividends or be deemed the holder of the Preferred Stock or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be
construed to confer upon such holder, as such, any of the rights of a stockholder of the company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action, whether upon any recapitalization, issuance of stock, reclassification of stock change of par value,
consolidation, merger, conveyance, or otherwise, or to receive dividends or subscription rights or otherwise until this Warrant shall have been exercised and the Preferred Stock purchasable upon the exercise hereof shall have become deliverable as
provided herein. 
 (n) Counterparts. This Warrant and any amendments, waivers, consents or supplements hereto may be executed in any
number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 
 [Remainder of Page Intentionally Left Blank] 
  

 12. 

 IN WITNESS WHEREOF, the parties hereto have caused this Warrant to be executed by its officers thereunto
duly authorized as of the Effective Date. 
  

									
	COMPANY:	 		 	TRANSORAL PHARMACEUTICALS, INC.
					
		 		 		 	By:	 	/s/ Illegible
		 		 		 	Title:	 	 
					
		 		 		 		 	 Attn: Tom Soloway, Chief Financial Officer
 300 Tamal
Plaza
 Corte Madera, CA 94925

			
	WARRANTHOLDER:	 		 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
					
		 		 		 	By:	 	/s/ Illegible
		 		 		 	Title:	 	Chief Legal Officer
					
		 		 		 		 	 Hercules Technology Growth Capital, Inc.
 Attn: Kathy
Conte
 525 University Ave, Suite 700
 Palo Alto, CA
94301

					
		 		 		 	cc:	 	 Hercules Technology Growth Capital, Inc.
 Attn: Chief
Legal Officer
 525 University Avenue
 Suite 700
 Palo Alto, CA 94301

  

 13. 

 EXHIBIT II 
 ACKNOWLEDGMENT OF EXERCISE 
 The undersigned TransOral Pharmaceuticals, Inc., hereby acknowledge receipt of the “Notice
of Exercise” from Hercules Technology Growth Capital, Inc., to purchase [____] shares of the Series C Preferred Stock of TransOral Pharmaceuticals, Inc., pursuant to the terms of the Agreement, and further acknowledges that [______] shares
remain subject to purchase under the terms of the Agreement. 
  

									
	COMPANY:	 		 	TRANSORAL PHARMACEUTICALS, INC.
					
		 		 		 	By:	 	 
		 		 		 	Title:	 	 
		 		 		 	Date:	 	 

  

 14. 

 EXHIBIT III 
 TRANSFER NOTICE 
 (To transfer or assign the foregoing Agreement execute this form and supply required information. Do not
use this form to purchase shares.) 
 FOR VALUE RECEIVED, the foregoing Agreement and all rights evidenced thereby are hereby transferred and assigned to

 _______________________________________________________________ 
 (Please Print) 
 whose address is __________________________________________________ 
 _______________________________________________________________ 
 Dated: ________________________________

 Holder’s Signature: _________________________________ 
 Holder’s Address: __________________________________ 
 ________________________________________________

  

 15. 

 EXHIBIT IV 
 JOINDER AGREEMENT 
 WHEREAS, the undersigned Hercules Technology Growth Capital, Inc. (the “Joining
Party”) and TransOral Pharmaceuticals, Inc., a Delaware corporation (the “Company”), have entered into a certain Loan and Security Agreement (the “LSA”), dated as of April 13, 2006, and certain other
related agreements contemplated thereby, pursuant to which, among other things, the Company will issue to the Joining Party one or more Warrants (the “Warrant”) to purchase an aggregate of up to 434,783 shares of the Company’s
Series C Preferred Stock, at an exercise price of $1.15 per share (the “Shares”); 
 WHEREAS, the parties hereto desire the
Joining Party to have certain registration rights with respect to the shares of Common Stock of the Company issuable upon conversion of the Shares pursuant to Sections 1.02, 1.03 and 1.15 of that certain Investors’ Rights Agreement, dated as of
October 25, 2005, among the Company and the other parties named therein, as the same may be amended and/or restated from time to time (the “Rights Agreement”), and that the Joining Party be added to the Rights Agreement as
parties thereto for the purpose of granting such registration rights; 
 WHEREAS, Section 3.14 of the Rights Agreement allows the
amendment or waiver of such Rights Agreement with the written consent of the Company and the holders of at least 66 2/3% of the Registrable Securities, as defined therein, outstanding (the “Supermajority Holders”); and

 WHEREAS, Article V, Section E(3) of the Company’s Amended and Restated Certificate of Incorporation (the
“Certificate”) provides that the Supermajority Holders consent to those certain transactions as proposed in the Warrant and LSA. 
 NOW,
THEREFORE, in consideration of the promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged by the parties hereto, the parties hereby covenant and agree as follows:

 1. The shares of Common Stock of the Company issuable upon conversion of the Shares shall constitute “Registrable
Securities,” as such term is defined in Section 1.01(k) of the Rights Agreement, for all intents and purposes of the registration rights and related provisions and obligations set forth in Sections 1.01 through 1.16 inclusive and Section 3
of the Rights Agreement. 
 2. The Joining party shall be treated for all purposes under Section 1.01 through 1.16 inclusive, and
Section 3 of the Rights Agreement as “Holders,” as such term is defined in Section 1.01(f) of the Rights Agreement. 
 3. The Joining Party agrees to be bound by the terms and conditions of Sections 1.01 through 1.16 inclusive and Section 3 of the Rights Agreement and shall succeed to and assume all of the rights and obligations of Holders of
Registrable Securities for all intents and purposes of such Sections, provided that, the Joining Party shall not be deemed to possess any rights set forth in Section 2 of the Rights Agreement. 
  

 16. 

 4. All notices and other communications under the Rights Agreement shall be made to the Joining
Party at the address specified below and thereafter at such other address, notice of which is given in accordance with Section 3.04 of the Rights Agreement: 
 Hercules Technology Growth Capital, Inc. 
 Attn: Kathy Conte 
 525 University Ave, Suite 700 
 Palo Alto,
CA 94301 
  

	 	cc:	Hercules Technology Growth Capital, Inc. 

 Attn: Chief
Legal Officer 
 525 University Avenue 
 Suite 700 
 Palo Alto, CA 94301 
 5. The undersigned hereby consent to the sale and issuance by the Company of the Warrant, and hereby waive on behalf of themselves and all other such holders the right of first offer granted to such holders
pursuant to Section 2.01 of the Rights Agreement. The undersigned hereby further consents to and waives (i) any prior notice periods that may be contained in the Rights Agreement, or in any other documents or instrument that provides for
prior notice of the sale and issuance of the Warrant pursuant to the LSA, and (ii) any requirements as set forth in Article V, Section E(3) of the Certificate in connection with the LSA, the Warrant, or any transactions contemplated thereby.

 6. The Rights Agreement as modified herein shall remain in full force and effect as so modified 
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written
above. 
  

			
	TRANSORAL PHARMACEUTICALS, INC.
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
	
	INVESTORS:

 See attached pages. 
 Agreed and Accepted: 
  

 17. 

			
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
		
	By:	 	 
		
	Title:	 	 

  

 18.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]